| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
EsoMeprazole (MagnesiuM salt) manufacturers
|
| | EsoMeprazole (MagnesiuM salt) Basic information |
| | EsoMeprazole (MagnesiuM salt) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | EsoMeprazole (MagnesiuM salt) Usage And Synthesis |
| Uses | Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3]. | | in vivo | Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. | Animal Model: | C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] | | Dosage: | 30 mg/kg, 300 mg/kg | | Administration: | Oral gavage; daily; for 19 or 11 days | | Result: | Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
|
| | References | [1] Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. DOI:10.18433/j34608
[2] Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. DOI:10.3389/fphar.2017.00016
[3] Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. DOI:10.1093/ajhp/59.14.1333 |
| | EsoMeprazole (MagnesiuM salt) Preparation Products And Raw materials |
|